Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.
What's in the News
- Puma Biotechnology provided new earnings guidance for the Fourth Quarter 2025, expecting total revenue between $67 million and $70 million, with net income forecasted at $9 million to $11 million. (Key Developments)
- The company raised its full-year 2025 earnings guidance and now projects total revenue of $220 million to $223 million, up from the previous range of $212 million to $222 million. (Key Developments)
- Full-year net income guidance for 2025 was also increased to $27 million to $29 million, compared to earlier estimates of $23 million to $28 million. (Key Developments)
Valuation Changes
- Fair Value: Unchanged at $3.50 per share.
- Discount Rate: Increased slightly from 7.21% to 7.31%.
- Revenue Growth: Remains essentially steady at 97.4%.
- Net Profit Margin: Stable at approximately 11.0%.
- Future P/E Ratio: Decreased modestly from 9.68x to 9.35x.
Have other thoughts on Puma Biotechnology?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.